Aims: To quantify healthcare resource utilization (HRU) and costs by disease stage in individuals with Huntington's disease (HD) in a US population.
Materials And Methods: This retrospective cohort study used administrative claims data from the IBM MarketScan Commercial, Multi-State Medicaid, and Medicare Supplemental Databases between 1 January 2009 and 31 December 2018. Individuals with an HD claim between 1 January 2010 and 31 December 2017 were selected. Index date was the date of first HD diagnosis. Individuals were required to have continuous enrollment for ≥ 12 months pre-index, 3 months post-index, and have no pre-index HD claims. All-cause HRU and costs per patient per month (PPPM) (overall and stratified by disease stage) were assessed for individuals with HD.
Results: A total of 2,669 individuals with HD were identified. Of these, 1,432 (53.7%), 689 (25.8%), and 548 (20.5%) had early-, middle-, and late-stage HD at baseline, respectively. Mean HRU PPPM by post-index HD stage increased with disease stage for outpatient visits, pharmacy claims, and HD-related pharmacy claims ( < 0.05 for all). Mean inpatient visits and emergency room visits PPPM were highest in individuals with middle-stage HD ( <0.05 for all). Mean total all-cause healthcare cost PPPM for individuals with HD was $2,889, and it was significantly higher in middle-stage individuals, at $7,988, compared with early- and late-stage individuals, at $3,726 and $5,125, respectively; <0.0001.
Limitations: In the absence of disease staging information in administrative claims data, staging was based on the presence of clinical markers in claims. Our evaluations didn't include the indirect costs of HD, which may be substantial as HD typically affects people at their peak earning potential.
Conclusions: HRU and costs of care are high among individuals with HD, particularly among those with middle- and late-stage disease. This indicates that the disease burden in HD increases with disease stage, highlighting the need for interventions that can slow or prevent disease progression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13696998.2022.2076997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimization of x-ray dark-field CT for human-scale lung imaging.
Med Phys
January 2025
Department of Engineering Physics, Tsinghua University, Beijing, China.
Background: X-ray grating-based dark-field imaging can sense the small angle scattering caused by object's micro-structures. This technique is sensitive to the porous microstructure of lung alveoli and has the potential to detect lung diseases at an early stage. Up to now, a human-scale dark-field CT (DF-CT) prototype has been built for lung imaging.
View Article and Find Full Text PDFStratified Impact of Therapies on Anaplastic Thyroid Cancer Outcomes in the Pre-Gene-Targeted Therapy Era.
Ann Surg Oncol
January 2025
Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Anaplastic thyroid cancer (ATC) is a highly lethal disease, often diagnosed with advanced locoregional and distant metastases, resulting in a median survival of just 3-5 months. This study determines the stratified effectiveness of baseline treatments in all combinations, enabling precise prognoses prediction and establishing benchmarks for advanced therapeutic options.
Methods: The study extracted a cohort of pathologically confirmed ATC patients from the Surveillance, Epidemiology, and End Results program.
Pericapsular nerve group cryoneurolysis as an option for palliative nonoperative management of hip fracture in a patient with end-stage medical comorbidities.
Can J Anaesth
January 2025
Department of Anesthesiology, Perioperative and Pain Medicine, Alberta Health Services and Cumming School of Medicine, University of Calgary, South Health Campus, 4448 Front St. SE, Calgary, AB, T3M 1M4, Canada.
Purpose: We report the use of a pericapsular nerve group (PENG) cryoneurolysis for longer-term analgesia in a patient with a hip fracture and severe medical comorbidities as an alternative to hip fracture surgery.
Clinical Features: A frail but lucid and fully autonomous 97-yr-old female from an assisted living facility sustained a subcapital fracture of her right proximal femur following a ground level fall. She had significant comorbidities including end-stage respiratory disease.
Multi-class Classification of Retinal Eye Diseases from Ophthalmoscopy Images Using Transfer Learning-Based Vision Transformers.
J Imaging Inform Med
January 2025
College of Engineering, Department of Computer Engineering, Koç University, Rumelifeneri Yolu, 34450, Sarıyer, Istanbul, Turkey.
This study explores a transfer learning approach with vision transformers (ViTs) and convolutional neural networks (CNNs) for classifying retinal diseases, specifically diabetic retinopathy, glaucoma, and cataracts, from ophthalmoscopy images. Using a balanced subset of 4217 images and ophthalmology-specific pretrained ViT backbones, this method demonstrates significant improvements in classification accuracy, offering potential for broader applications in medical imaging. Glaucoma, diabetic retinopathy, and cataracts are common eye diseases that can cause vision loss if not treated.
View Article and Find Full Text PDFEfficacy and safety of teriparatide in kidney transplant recipients with osteoporosis and low bone turnover: a real-world experience.
Int Urol Nephrol
January 2025
Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD), enhancing survival and quality of life. However, kidney transplant recipients (KTRs) are at high risk for bone disorders, particularly low bone turnover disease, which increases fracture risk. Teriparatide, an anabolic agent, may provide a beneficial treatment option for these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!